Edwards Lifesciences (EW)
(Delayed Data from NYSE)
$68.93 USD
+0.18 (0.26%)
Updated Sep 4, 2024 04:00 PM ET
After-Market: $68.93 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
C Value F Growth D Momentum F VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$68.93 USD
+0.18 (0.26%)
Updated Sep 4, 2024 04:00 PM ET
After-Market: $68.93 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
C Value F Growth D Momentum F VGM
Zacks News
Edwards Lifesciences' CE Mark for SAPIEN 3 Boosts THVT Arm
by Zacks Equity Research
Latest CE Mark receipt is expected to fortify Edwards Lifesciences' (EW) position in Europe.
Edwards Lifesciences (EW) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
Edwards Lifesciences (EW) closed the most recent trading day at $149.75, moving -1.99% from the previous trading session.
The Zacks Analyst Blog Highlights: Boeing, Texas Instruments, General Dynamics, American International, TD Ameritrade and Edwards Lifesciences
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Boeing, Texas Instruments, General Dynamics, American International, TD Ameritrade and Edwards Lifesciences
Top Stock Reports for Boeing, Texas Instruments & General Dynamics
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Boeing (BA), Texas Instruments (TXN) and General Dynamics (GD).
Edwards Lifesciences (EW) Earnings Beat, Revenues Miss in Q3
by Zacks Equity Research
Edwards Lifesciences (EW) gains from THVT strength on continued therapy adoption across all geographies in Q3.
The Most Spectacular Earnings Charts This Week
by Tracey Ryniec
Investors aren't spooked in these stocks. They have great earnings track records and shares are trading near their highs.
EW, VAR Earnings Due on Oct 23: Here Are Key Predictions
by Zacks Equity Research
Both Edwards Lifesciences (EW) and Varian Medical (VAR) are brimming with prospects despite the current political disarray within the medical instruments space.
Medidata (MDSO) Tops Earnings & Revenue Estimates in Q3
by Zacks Equity Research
Strong performance in the Subscription revenues segment drives Medidata???s (MDSO) results in Q3. Professional services also posted steady growth.
Is a Surprise Coming for Edwards Lifesciences (EW) This Earnings Season?
by Zacks Equity Research
Edwards Lifesciences (EW) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Edwards Lifesciences (EW) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
Edwards Lifesciences (EW) closed the most recent trading day at $145.51, moving -1.23% from the previous trading session.
Intuitive Surgical (ISRG) Beats on Q3 Earnings & Revenues
by Zacks Equity Research
Strong performance in the Instruments & Accessories and Systems segments drive Intuitive Surgical's (ISRG) top line in Q3.
Will Edwards' (EW) Steady Overall Growth Drive Q3 Earnings?
by Zacks Equity Research
Edwards Lifesciences (EW) expected to gain from strength in all business segments and geographies in Q3.
Abbott (ABT) Q3 Earnings Top Estimates, Guidance Narrowed
by Zacks Equity Research
Within Structural Heart, growth was driven by several product areas across Abbott's (ABT) broad portfolio, including AMPLATZER PFO Occluder and MitraClip.
Bear of the Day: Newmont Mining (NEM)
by Kevin Cook
Gold back above $1200 is encouraging for miners, but the long-term bear market is still in charge
Edwards Lifesciences (EW) Q3 Earnings Preview: Here's What to Look Out For
by Zacks Equity Research
Edwards Lifesciences (EW) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Is Edwards Lifesciences (EW) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Is (EW) Outperforming Other Medical Stocks This Year?
Can Edwards Lifesciences (EW) Keep the Earnings Surprise Streak Alive?
by Zacks Equity Research
Edwards Lifesciences (EW) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Edwards Begins US CENTERA Study, Reintroduces Valve in Europe
by Zacks Equity Research
Edwards (EW) is recommencing commercial introduction of CENTERA valve in Europe after making certain minor modification to CENTERA's delivery system.
Zacks Market Edge Highlights: Intuitive Surgical, BioTelemetry, Edwards Lifesciences, Penumbra and Vericel
by Zacks Equity Research
Zacks Market Edge Highlights: Intuitive Surgical, BioTelemetry, Edwards Lifesciences, Penumbra and Vericel
How to Invest in the Hot Medical Device Innovators
by Tracey Ryniec
Forget the biotechs. Medical device companies are innovating in amazing ways. Here's how to invest.
4 MedTech Stocks to Counter Mounting US-China Trade Tensions
by Sweta Jaiswal
In the wake of the impact of the U.S.-China trade war on the MedTech space, we have doubled down on some stocks which offer a safe haven to investors.
Here's Why You Should Add Edwards Lifesciences Right Away
by Zacks Equity Research
We are upbeat about the continued strength in Edwards Lifesciences' (EW) THVT business.
Edwards Lifesciences (EW) in Focus: Stock Moves 7.7% Higher
by Zacks Equity Research
Edwards Lifesciences (EW) saw a big move last session, as its shares jumped nearly 8% on the day, amid huge volumes.
Bull of the Day: Penumbra (PEN)
by Kevin Cook
Innovation in stroke treatment with catheter-based technologies has launched a new rocket of med-tech
Here's Why You Should Steer Clear of AmerisourceBergen Now (Revised)
by Zacks Equity Research
AmerisourceBergen (ABC) continues to witness headwinds due to slowdown in hepatitis C revenues and conversion of branded drugs to the lower price generics.